Tema Etfs LLC Invests $503,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)

Tema Etfs LLC bought a new position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 89,239 shares of the company's stock, valued at approximately $503,000. Tema Etfs LLC owned about 0.11% of Verve Therapeutics as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. IFP Advisors Inc raised its position in shares of Verve Therapeutics by 823,700.0% during the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock valued at $47,000 after acquiring an additional 8,237 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Verve Therapeutics during the fourth quarter valued at $50,000. Impact Partnership Wealth LLC acquired a new stake in shares of Verve Therapeutics during the fourth quarter worth $70,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Verve Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company's stock worth $101,000 after buying an additional 1,676 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Verve Therapeutics in the 4th quarter worth about $101,000. Institutional investors and hedge funds own 97.11% of the company's stock.

Verve Therapeutics Price Performance

Shares of NASDAQ VERV traded down $0.38 during midday trading on Wednesday, hitting $4.23. 2,799,371 shares of the company's stock were exchanged, compared to its average volume of 1,858,494. The stock's 50 day moving average price is $4.71 and its 200-day moving average price is $5.84. The firm has a market cap of $377.07 million, a P/E ratio of -1.72 and a beta of 1.82. Verve Therapeutics, Inc. has a twelve month low of $2.86 and a twelve month high of $9.31.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The company had revenue of $32.98 million during the quarter, compared to analyst estimates of $7.13 million. On average, analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Royal Bank of Canada cut their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Cantor Fitzgerald raised Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, April 15th. Guggenheim upped their price objective on Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. Canaccord Genuity Group raised their target price on Verve Therapeutics from $32.00 to $39.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. Finally, William Blair reissued an "outperform" rating on shares of Verve Therapeutics in a report on Friday, February 21st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verve Therapeutics has an average rating of "Buy" and an average target price of $25.75.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.